Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study.

Détails

Ressource 1Télécharger: 33603005_BIB_8A087AFA31EC.pdf (1691.79 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_8A087AFA31EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study.
Périodique
Scientific reports
Auteur(s)
Bourdin A., Schneider M.P., Locatelli I., Schluep M., Bugnon O., Berger J.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
18/02/2021
Peer-reviewed
Oui
Volume
11
Numéro
1
Pages
4107
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety data (patient-reported symptoms, discontinuations due to adverse events (AEs), repeated first-dose monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, influence of covariates, barriers and facilitators) were described. Sixty-seven patients joined the F-PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients repeated the first-dose monitoring. Patients had a high medication adherence over the 18-month analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients' level of education, professional situation, and living with child(ren) influenced implementation. Patients reported more facilitators of medication adherence than barriers. The F-PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod and inviting patients for shared-decision making) and public health (indirectly gathering real-world evidence).
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/02/2021 11:24
Dernière modification de la notice
30/04/2021 6:12
Données d'usage